Вирусный гепатит С

Острый или хронический вирусный гепатит С не является прямым противопоказанием для прекращения цитостатической терапии. В данном случае курс химиотерапии должен проводиться при строгом мониторинге печёночных проб (АЛТ, АСТ, общий билирубин, билирубин прямой) и вирусной нагрузки – проведение ПЦР 1 раз/месяц (количественное определение копий).

Стандартную противовирусную терапию гепатита С необходимо проводить пациентам, вышедшим из миелосупрессии более 6 месяцев назад. Рекомендуется введение Пегилированного интерферона и Рибавирина. Доза препаратов, частота и кратность введения определяется для каждого пациента индивидуально после консультации инфекциониста и гепатолога.

Литература

1. SiegelR., NaishadhamD., Jemal Ah.Cancer statistics, 2012 CA: A Cancer Journal for Clinicians Volume 62, Issue 1, pages 10–29, January/February 2012.

2. ShaikhM.U., AliN., AdilS.N., KhurshidM. Outcomeofadultpatientswithacutelymphoblastic leukaemia receiving the MRC UKALL XII protocol: a tertiary care centre experience Singapore Med J. 2011 May;52(5):370-4.

3. Tangen J.M., Fløisand Y., Haukås E., Naess I.A., Skjelbakken T., Stapnes C., Tjønnfjord G.E. Survival in adults with acute lymphoblastic leukaemia Tidsskr Nor Laegeforen. 2010 Sep 9;130(17):1710-3.

4. ПаровичниковаЕ. Н., ДавидянЮ. Р., ИсаевВ. Г., СоколовА. Н., КлясоваГ. А., Менделеева Л. П. Итоги лечения острых лимфобластных лейкозов взрослых по протоколу ОЛЛ-2005 как основа для новых исследований. Терапевтический архив №7 2009.

5. Gökbuget N., Hoelzer D. Treatment of Adult Acute Lymphoblastic Leukemia. Seminars inHematology. 2009;46(1):64-75.

6. Bassan R., Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543.

7. GökbugetN., KnebaM., RaffTh., TrautmannH., BartramC-R., Arnold R.et al. Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Blood. 2012 Aug 30;120(9):1868-1876.

8. Folber F., Sálek C., Doubek M., Soukupová Maaloufová J, Valová T, Trka J. et al. Treatment of adult acute lymphoblastic leukemia according to GMALL 07/2003 study protocol in the Czech Republic - the first experience Vnitr Lek. 2010 Mar;56(3):176-82. (abstr).

9. Hoelzer D., Thiel E., Loffler H. et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988 71:123–131

10. Ludwig W.D., Rieder H., Bartram C.R., Heinze B., Schwartz S., Gassmann W., Löffler H. et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89 Blood. 1998 Sep 15;92(6):1898-909.

11. Gokbuget N., Hoelzer D., Arnold R. et al. Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hemat/Oncol Clin North Am. 2000 14:1307–1325.

12. Hoelzer D., Gökbuget N., Digel W., Faak T., Kneba M. et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia Blood. 2002 Jun; 15;99(12):4379-85.

13. Gokbuget N., Baur K-H., Beck J. et al. Dexamethasone dose and schedule significantly influences remission rate and toxicity of induction therapy in adult acute lymphoblastic leukemia (ALL): Results of the GMALL pilot trial 06/99 [abstract]. Blood. 2005 106:1832.

14. Annino L., Vegna M.L., Camera A., Specchia G. et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.Blood, 2002;Feb. 99(3): 863-871.

15. Murphy S.B., Bowman W.P., Hustu H.O., Berard C.W. Advanced stage (III-IV) Burkitt's lymphoma and B-cell acute lymphoblastic leukaemia in children: kinetic and pharmacologic rationale for treatment and recent results (1979-1983) ARC Sci Publ. 1985;(60):405-18.

16. Murphy S.B., Bowman W.P., Abromowitch M., Mirro J. et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine J Clin Oncol. 1986 Dec;4(12):1732-9.

17. Kantarjian H.M., O'Brien S., Smith T.L., Cortes J. et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia J Clin Oncol. 2000 Feb;18(3):547-61.

18. Thomas D., O'Brien S., Faderl S., Ravandi F. et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in thecontext of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen Cancer. 2010 Oct 1;116(19):4580-9.

19. Thomas D.A. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges Hematology Am Soc Hematol Educ Program. 2007:435-43.

20. Thomas D.A., Faderl S., Cortes J., O'Brien S. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood. 2004 Jun 15;103(12):4396-407.

21. Thomas D.A., O'Brien S., Faderl S., Garcia-Manero G. et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia J Clin Oncol. 2010 Aug 20;28(24):3880-9.

22. Pui C.H., Evans W.E.Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.

23. Todeschini G., Tecchio C., Meneghini V. et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998;12:144-149.

24. Saarinen U.M., Mellander L., Nysom K. et al. Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective casecontrol study in the Nordic countries. Bone Marrow Transplant. 1996;17:357-363.

25. Annino L., Vegna M.L., Camera A. et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863-871.

26. Bostrom B.C., Sensel M.R., Sather H.N., Gaynon P.S. et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group Blood. 2003 May 15;101(10):3809-17.

27. Teuffel O., Kuster S.P., Hunger S.P., Conter V. et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis Leukemia. 2011 Aug;25(8):1232-8.

28. Labar B., Suciu S., Willemze R., Muus P. et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group Haematologica. 2010 Sep;95(9):1489-95.

29. Michael E Rytting Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients Blood and Lymphatic Cancer: Targets and Therapy 2012:2 117–124.

30. Wetzler M., Sanford B.L., Kurtzberg J., DeOliveira D. et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 Blood. 2007 May 15;109(10):4164-7.

31. Vassilios I Avramis, Prakash Nidhi Tiwari Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia International Journal of Nanomedicine 2006:1(3) 241–254.

32. Hoelzer D., Gökbuget N., Ottmann O., Pui C.H. et al. Acute lymphoblastic leukemia Hematology Am Soc Hematol Educ Program. 2002:162-92.

33. РумянцеваЮ.В., КарачунскийА.И., Румянцев А.Г. Оптимизация терапии острого лимфобластного лейкоза у детей в россии Педиатрия. 2009; 87(4): 19-27.

34. Bassan R., Hoelzer D. Modern therapy of acute lymphoblastic leukemia J Clin Oncol. 2011 Feb 10;29(5):532-43.

35. Gökbuget N., Kneba M., Raff T., Trautmann H. et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Blood. 2012 Aug 30;120(9):1868-76.

36. Lazarus H.M., Richards S.M., Chopra R. et al: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: Results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006; 108:465-472.

37. Thomas X., Boiron J.M., Huguet F. et al: Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 2004; 22:4075-4086.

38. Teuffel O., Kuster S.P., Hunger S.P., Conter V. et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis Leukemia. 2011 Aug;25(8):1232-8.

39. Jabbour E.J., Faderl S., Kantarjian H.M. Adult acute lymphoblastic leukemia Mayo Clin Proc. 2005 Nov;80(11):1517-27.

40. Bassan R., Hoelzer D. Modern therapy of acute lymphoblastic leukemia J Clin Oncol. 2011 Feb 10;29(5):532-43.

41. Thiebaut A., Vernant J.P., Degos L. et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000;14:1353-1366.

42. Labar B., Suciu S., Zittoun R. et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for patients < or = 50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica. 2004;89:809-817.

43. Ribera J.M., Oriol A., Bethencourt C. et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.Haematologica. 2005;90:1346-1356.

44. Chaidos A., Kanfer E., Apperley J.F. Risk assessment in haemotopoietic stem cell transplantation: Disease and disease stage. Best Pract Res Clin Haematol. 2007; 20: 125- 154.

45. Loberiza F. Summary Slides 2003 - part III. IMBTR/ABMTR Newsletter 2006; 10: 6-9.

46. Yanada M., Matsuo K., Suzuki T., Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer 2006; 106: 1657-1663.

47. Richard A. Larson Allogeneic Hematopoietic Cell Transplantation Is Not Recommended for all Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission Biol Blood Marrow Transplant 15: 11-16 (2009)

48. Kantarjian H.M., Thomas D., O’Brien S. et al. Long-termfollow-up results of hyperfractionated cyclophosphamide,vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocyticleukemia. Cancer. 2004;101:2788-2801.

49. Hoelzer D., Thiel H., Loffler H. et al. Prognostic factors ina multicenter study for treatment of acute lymphoblasticleukemia in adults. Blood. 1988;71:123-131.

50. Goldstone A.H., Richards S.M., Lazarus H.M. et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: Final results of the International ALL trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008

51. Pui C.H., Evans W.E.Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.

52. Ribera J.M., Oriol A., Bethencourt C. et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.Haematologica. 2005;90:1346-1356.

53. Arnold R., Beelen D., Bunjes D., et al. Phenotype predicts outcome after allogeneic stem cell transplantation in adult high risk ALL patients. Blood. 2003;102:abstract #1719.

54. Béné M.C., Castoldi G., Knapp W. et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783–1785.

55. Behm F.B., Campana D. Immunophenotyping In: Childhood Leukemias. Pui C.H., ed. Cambridge: Cambridge Univiversity Press, 1999.p. 111.

56. GökbugetN., Stanze D., BeckJ., DiedrichH. et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation Blood 2012 Sep;120(10): 2032-2041.

57. Fielding A.K. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia Blood. 2010 Nov 4;116(18):3409-17.

58. Rowe J.M., Buck G., Burnett A.K. et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760-3767.

59. Preti H.A., O’Brien S., Giralt S., Beran M. et al. Philadelphia-chromosome–positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994;97(1):60-65.

60. de Labarthe A., Rousselot P., Huguet-Rigal F., Delabesse E. et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study Blood. 2007 Feb 15;109(4):1408-13.

61. Chalandon Y., Thomas X., Hayette S. et al. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia. Blood. 2008;112(11):Abstract 12.